Neuromuscular Weakness

📋 Key Information Summary

📋

Neuromuscular weakness encompasses disorders of the anterior horn cell, peripheral nerve, neuromuscular junction, and muscle — each producing recognisable clinical patterns that guide diagnosis in primary care.
Proximal weakness (difficulty rising from a chair, climbing stairs, overhead tasks) suggests myopathy or neuromuscular junction disorder; distal weakness (foot drop, grip weakness) points to peripheral neuropathy or motor neuron disease.
Areflexia or hyporeflexia with acute or subacute weakness is a red flag for Guillain–Barré syndrome (GBS) and requires urgent hospital referral.
Fatigability — weakness worsening with repeated use and improving with rest — is the hallmark of myasthenia gravis (MG) and should prompt acetylcholine receptor antibody testing.
Respiratory red flags — dyspnoea at rest, orthopnoea, weak cough, difficulty swallowing, nasal speech — may indicate impending respiratory failure in GBS or myasthenic crisis; these patients require emergency department assessment and ICU-level monitoring.
Guillain–Barré syndrome presents as rapidly progressive bilateral flaccid weakness with areflexia, often ascending from the legs; nerve conduction studies confirm demyelination; IV immunoglobulin (IVIg) or plasma exchange are first-line treatments.
Myasthenic crisis is a life-threatening exacerbation causing respiratory failure; requires intubation, IVIg or plasma exchange, and ICU admission. Distinguish from cholinergic crisis clinically and with edrophonium testing or ice-pack test.
Spinal cord compression — acute bilateral leg weakness, sensory level, urinary retention, and bowel dysfunction — is a neurological emergency requiring emergent MRI and decompression within 24 hours.
Inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis) present with subacute proximal weakness and elevated CK; anti-Jo-1, anti-Mi-2, and anti-SRP antibodies guide classification and prognosis.
Hereditary myopathies (facioscapulohumeral dystrophy, limb-girdle dystrophy, myotonic dystrophy) typically present with insidious onset, family history, and characteristic patterns such as facial weakness or myotonia.
Baseline investigations for suspected myopathy include serum CK, ESR/CRP, thyroid function, serum electrolytes (potassium, calcium, magnesium), autoimmune screen (ANA, ENA, myositis-specific antibodies), and HbA1c for statin-related myopathy.
Aboriginal and Torres Strait Islander Australians may present later due to barriers to specialist access; culturally safe screening, awareness of delayed presentations, and supported referral pathways are essential.
Muscle biopsy, electromyography (EMG), and nerve conduction studies (NCS) are available in major Australian centres; telehealth and fly-in specialist services support regional and remote assessment.

Introduction & Australian Epidemiology

Neuromuscular weakness refers to impairment of strength arising from disease at any point along the motor pathway: the anterior horn cells (motor neuron disease), peripheral nerves (neuropathies including GBS), the neuromuscular junction (myasthenia gravis, Lambert–Eaton syndrome), or the muscle itself (myopathies and muscular dystrophies). Accurate localisation is the critical first step in evaluation, and the pattern of weakness — proximal versus distal, symmetric versus asymmetric, with or without sensory involvement — provides the essential clue.

In Australia, neuromuscular disorders collectively affect tens of thousands of individuals. Myasthenia gravis has an estimated prevalence of approximately 150–250 per million population, with a bimodal age of onset peaking in women aged 20–30 and men aged 60–80. Guillain–Barré syndrome occurs in approximately 1–2 per 100,000 person-years, with a mean age of onset around 40 years. Inflammatory myopathies have an incidence of approximately 5–10 per million per year, while hereditary muscular dystrophies such as myotonic dystrophy type 1 affect approximately 1 in 8,000 Australians. Motor neuron disease (MND) has an incidence of approximately 2–3 per 100,000 per year, with a median survival of 2–3 years from diagnosis.

Aboriginal and Torres Strait Islander Australians may experience higher rates of diabetes-related neuropathy and delayed diagnosis of neuromuscular conditions due to geographic isolation and barriers to specialist access. National surveillance data from the Australian Institute of Health and Welfare (AIHW) and the Australian Neuromuscular Disease Registry highlight the need for improved access to diagnostic services in rural and remote areas.

ℹ️

The Australian Neuromuscular Disease Registry (ANMDR), coordinated through the Murdoch Children's Research Institute, collects nationwide data to improve clinical care and research outcomes for Australians living with neuromuscular conditions.

Screening in Primary Care

The general practitioner is often the first clinician to evaluate a patient with neuromuscular weakness. A structured approach to history and examination allows rapid identification of the localisation (anterior horn cell, nerve, junction, muscle), urgency of referral, and the most appropriate initial investigations.

Pattern of Weakness

The distribution of weakness is the single most important clinical clue:

Pattern	Typical Activities Affected	Localisation	Examples
Proximal	Rising from chair, climbing stairs, brushing hair, overhead tasks	Muscle (myopathy) or NMJ	Inflammatory myopathy, statin myopathy, myasthenia gravis, limb-girdle dystrophy
Distal	Foot drop, tripping, difficulty with buttons/keys, grip weakness	Peripheral nerve or anterior horn cell	Charcot–Marie–Tooth disease, distal myopathy, motor neuron disease, peripheral neuropathy
Focal / Asymmetric	Unilateral hand weakness, single leg dragging	Nerve root, plexus, or anterior horn cell	Radiculopathy, brachial plexopathy, MND (early), mononeuritis multiplex
Bulbar	Dysarthria, dysphagia, nasal speech, difficulty chewing	Brainstem, NMJ, or bulbar muscles	Myasthenia gravis, bulbar MND, brainstem stroke
Ascending / Symmetric	Bilateral leg weakness progressing to arms over days	Peripheral nerve (demyelinating)	Guillain–Barré syndrome

Reflexes

Deep tendon reflexes provide critical localising information:

Areflexia or generalised hyporeflexia — Guillain–Barré syndrome, severe peripheral neuropathy, advanced myopathy (CK often very high)
Normal reflexes in weak muscles — Consider neuromuscular junction disorder (myasthenia gravis) or early myopathy
Hyperreflexia with weakness — Suggests upper motor neuron pathology (spinal cord compression, motor neuron disease with UMN features); not a primary muscle or NMJ disorder
Reflex decrement with fatigability — May be seen in advanced MG but is not a reliable bedside sign

Fatigability

Fatigability — weakness worsening with repeated muscle use and improving with rest — is the hallmark of neuromuscular junction disorders, particularly myasthenia gravis. Bedside tests include:

Sustained upgaze test: Ask the patient to look upward for 60 seconds; development of ptosis or diplopia is positive.
Counting test: Ask the patient to count aloud from 1 to 50; progressive nasal speech, hypophonia, or inability to complete suggests bulbar fatigability.
Arm raise test: Hold arms abducted to 90° for 2 minutes; proximal drop suggests fatigable weakness.
Ice-pack test: Application of ice over a ptotic eyelid for 2 minutes — improvement of ptosis by ≥2 mm is suggestive of MG (sensitivity ~80%).

Respiratory Red Flags

🚨

Immediate assessment required: Any patient with neuromuscular weakness and signs of respiratory compromise must be referred to the emergency department without delay. Respiratory failure can develop rapidly in GBS and myasthenic crisis. Assess:

Dyspnoea at rest or on minimal exertion
Orthopnoea or inability to lie flat
Weak or ineffective cough
Difficulty swallowing (choking on saliva, nasal regurgitation)
Nasal speech or hypophonia
Accessory muscle use, paradoxical abdominal breathing
Forced vital capacity (FVC) <20 mL/kg or <1 L (if bedside spirometry available)

⚠️

Clinical pearl: In GBS, respiratory deterioration can occur over hours. Any patient with ascending weakness and areflexia should be assessed in hospital even if respiratory function appears normal at presentation — peak respiratory risk typically occurs within the first 2 weeks.

Urgent Conditions

Three conditions in neuromuscular weakness constitute neurological emergencies: Guillain–Barré syndrome, myasthenic crisis, and spinal cord compression. Rapid recognition and appropriate referral can prevent irreversible disability or death.

Guillain–Barré Syndrome (GBS)

GBS is an acute, immune-mediated polyradiculoneuropathy, most commonly the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant in Australia. It typically follows a respiratory or gastrointestinal infection by 1–4 weeks. Campylobacter jejuni is the most common precipitant worldwide.

Clinical Features

Bilateral, symmetric, ascending flaccid weakness — typically starting in the legs and progressing proximally
Areflexia or marked hyporeflexia in affected limbs
Sensory symptoms (paraesthesia, pain) — often present but motor predominates
Autonomic dysfunction — tachycardia, blood pressure fluctuations, urinary retention, ileus
Cranial nerve involvement — bilateral facial weakness (50%), bulbar weakness, ophthalmoplegia (Miller Fisher variant)
Miller Fisher variant — triad of ophthalmoplegia, ataxia, and areflexia with anti-GQ1b antibodies

Brighton Diagnostic Criteria (Modified)

Feature	Required for Clinical Diagnosis
Bilateral limb weakness	Required — progressive over days to 4 weeks
Areflexia or hyporeflexia	Required — generalised (in all affected limbs)
Monophasic course	Peak within 4 weeks, then plateau or improvement
Exclusion of alternative causes	Electrolyte disturbance, myelopathy, botulism, critical illness neuropathy
Nerve conduction studies / CSF	Supportive but not essential for clinical diagnosis if pattern is classic

Investigations

Nerve conduction studies / EMG: Demyelinating pattern (prolonged distal latencies, conduction block, temporal dispersion, F-wave prolongation) — available at major Australian hospitals; arrange urgently via neurology registrar
Lumbar puncture: Albuminocytological dissociation (elevated protein with normal cell count) — may be normal in the first week; do not delay treatment if clinical suspicion is high
Serum anti-ganglioside antibodies: Anti-GM1, anti-GD1a (AMAN variant), anti-GQ1b (Miller Fisher) — available through major pathology services (Sullivan Nicolaides, Douglass Hanly Moir, Melbourne Pathology)
Respiratory function: Serial FVC measurement — admission to HDU/ICU if FVC <20 mL/kg or declining rapidly
Autonomic monitoring: Continuous cardiac monitoring, blood pressure, urine output

Treatment

💊

Immunoglobulin (IVIg)

Intragam® P / Privigen® · First-line treatment

Adult dose 0.4 g/kg/day IV for 5 days (total 2 g/kg)

Paediatric dose 0.4 g/kg/day IV for 5 days (total 2 g/kg)

Route Intravenous infusion

Renal adjustment Reduce rate in renal impairment; monitor for thromboembolism and aseptic meningitis

PBS status ✔ PBS Authority Required

💊

Plasma Exchange (Plasmapheresis)

Alternative first-line — equal efficacy to IVIg

Regimen 5 exchanges over 8–10 days (200–250 mL/kg total volume)

Indication Severe GBS, especially if IVIg contraindicated (e.g. IgA deficiency, renal failure)

Availability Major tertiary hospitals — requires central venous access and apheresis team

PBS status ✔ Hospital-funded (non-PBS)

⚠️

No benefit from combining treatments: The evidence does not support IVIg followed by plasma exchange (or vice versa) for non-responders. If no improvement occurs after one course, consider alternative diagnoses. Corticosteroids are NOT effective in GBS.

Myasthenic Crisis

Myasthenic crisis is defined as exacerbation of myasthenia gravis causing respiratory failure requiring mechanical ventilation. It occurs in approximately 15–20% of patients with MG at some point in their disease course and carries a mortality rate of approximately 5–10% in modern ICUs.

Triggers

Infection (most common trigger — respiratory tract infections especially)
Medication changes — withdrawal of immunosuppression, initiation of aminoglycosides, fluoroquinolones, beta-blockers, magnesium, or neuromuscular blocking agents
Surgery, particularly thymectomy or any general anaesthesia
Heat, emotional stress, thyroid dysfunction
Pregnancy and the postpartum period

Clinical Recognition

Worsening bulbar weakness — dysphagia, nasal speech, inability to manage secretions
Progressive respiratory weakness — dyspnoea, shallow breathing, declining FVC
Generalised limb weakness
Distinguish from cholinergic crisis (excess anticholinesterase medication): cholinergic crisis features miosis, bradycardia, sweating, salivation, GI cramping — these features are absent in myasthenic crisis

Acute Treatment

💊

Immunoglobulin (IVIg)

Intragam® P / Privigen® · First-line for crisis

Adult dose 0.4 g/kg/day IV for 5 days (total 2 g/kg)

Onset of effect Improvement typically within 3–7 days

PBS status ✔ PBS Authority Required

💊

Plasma Exchange

Alternative first-line — equal efficacy

Regimen 5 exchanges over 10–14 days

Availability Tertiary hospitals only

PBS status ✔ Hospital-funded (non-PBS)

🚨

Critical management points in myasthenic crisis:

Intubate early if FVC <15 mL/kg, declining rapidly, or bulbar failure with aspiration risk
Avoid succinylammonium for rapid-sequence intubation — use rocuronium or propofol/ketamine with caution; prolonged paralysis may occur
Temporarily discontinue anticholinesterase agents (pyridostigmine) during acute crisis — they increase secretions and may worsen respiratory management
Screen for and treat triggers (infection, thyroid dysfunction, medication interactions)

Spinal Cord Compression

Spinal cord compression is a neurological emergency requiring rapid recognition and decompression. It may arise from metastatic disease (most common in Australia: lung, breast, prostate, kidney, colorectal), epidural abscess, haematoma, or acute disc herniation.

Clinical Features

Motor: Bilateral leg weakness (paraparesis or paraplegia), initially flaccid (spinal shock) then spastic
Sensory: Sensory level — band-like dermatomal distribution, posterior column loss (proprioception, vibration)
Sphincter: Urinary retention (often the earliest autonomic sign), constipation, bowel incontinence
Pain: Localised spinal pain, often worse when lying down (nocturnal exacerbation in metastatic disease), radicular pain
Reflexes: Initially areflexic (spinal shock), then hyperreflexic with extensor plantar responses (upper motor neuron signs)

Immediate Management

🚨

Time-critical intervention:

Emergent MRI of the whole spine — must be performed within 24 hours of suspected cord compression
Dexamethasone 10 mg IV stat, then 4 mg IV/PO QID — reduces vasogenic oedema; taper over 7–14 days
Surgical decompression — within 24 hours if operable; consult neurosurgery or spinal surgery urgently
Radiation oncology — for inoperable metastatic disease; emergency radiation therapy within 24–48 hours
Bladder management — indwelling catheter for urinary retention; monitor input/output

1

Recognise

Bilateral leg weakness + sensory level + sphincter dysfunction = cord compression until proven otherwise

2

Steroidise

Dexamethasone 10 mg IV immediately — do not wait for imaging

3

Image

Emergent MRI whole spine (with contrast if malignancy or abscess suspected)

4

Refer

Neurosurgery / spinal surgery and radiation oncology — within 24 hours

Chronic Myopathies

Chronic myopathies present with insidious progressive weakness, typically proximal, over weeks to months to years. The key clinical question in primary care is whether the presentation suggests an inflammatory myopathy (potentially treatable with immunosuppression) or a hereditary myopathy (requiring genetic diagnosis and supportive management).

Inflammatory vs Hereditary Myopathy — Clinical Clues

Feature	Inflammatory Myopathy	Hereditary Myopathy
Onset	Subacute (weeks to months)	Insidious (months to years); may present in childhood
Age at onset	Any age; dermatomyositis bimodal (paediatric + adult peaks); inclusion body myositis >50 years	Childhood/adolescence for Duchenne/Becker; variable for limb-girdle; 20–40 years for FSHD, myotonic dystrophy
Family history	Usually negative	Often positive — autosomal dominant (FSHD, myotonic dystrophy) or recessive (limb-girdle); X-linked (Duchenne, Becker)
CK level	Elevated 5–50× upper limit of normal (ULN); may be normal in IBM	Variable — markedly elevated in Duchenne/Becker (50–100× ULN); mildly elevated in FSHD; may be normal in some limb-girdle types
Skin changes	Present in dermatomyositis — heliotrope rash, Gottron's papules, V-sign, shawl sign, mechanic's hands	Absent
Myotonia	Absent	Present in myotonic dystrophy — inability to relax grip, percussion myotonia of thenar eminence
Pattern of weakness	Symmetric proximal; IBM: distal (finger flexors) + proximal + quadriceps	Facioscapulohumeral: face, scapular stabilisers, biceps; Limb-girdle: shoulder and hip girdle; Myotonic: distal (hands, feet) + facial
Response to steroids	Polymyositis and dermatomyositis — usually responsive; IBM — poor or absent response	Not responsive
Extramuscular features	Interstitial lung disease (anti-Jo-1), malignancy (dermatomyositis — ovarian, lung, GI, lymphoma), dysphagia, cardiac involvement	Cardiac involvement (myotonic dystrophy — conduction defects, cardiomyopathy); cataracts (myotonic dystrophy); respiratory muscle weakness

Inflammatory Myopathies — Detailed Approach

Polymyositis & Dermatomyositis

Dermatomyositis (DM) is characterised by proximal muscle weakness plus characteristic cutaneous features and carries a significant association with underlying malignancy (estimated 20–25% in adults). Polymyositis (PM) presents with isolated proximal weakness without skin changes. Both are more common in women.

Malignancy screening in adult dermatomyositis:

Age-appropriate cancer screening (colonoscopy, mammography, cervical screening, prostate-specific antigen)
CT chest/abdomen/pelvis with contrast
Pelvic ultrasound (ovarian malignancy screening — particularly important in women)
PET-CT if available and clinical suspicion remains high
Anti-TIF1-γ and anti-NXP2 antibodies are associated with cancer-associated DM
Screening should occur within 3 months of DM diagnosis and continue for 3–5 years

Inclusion Body Myositis (IBM)

IBM is the most common acquired myopathy in patients over 50 years and is often misdiagnosed as polymyositis. Key distinguishing features include:

Slowly progressive course (over years, not weeks)
Predominant involvement of finger flexors (difficulty opening jars, turning keys) and quadriceps (tendency to fall)
CK may be normal or only mildly elevated (2–5× ULN)
Poor or no response to immunosuppressive therapy — this is a critical distinction from PM/DM
Muscle biopsy shows endomysial inflammation with rimmed vacuoles (pathognomonic)
Associated with anti-cN1A (NT5C1A) antibodies

⚠️

Do not empirically treat for polymyositis without biopsy confirmation. IBM is common in older adults, does not respond to steroids or immunosuppression, and prolonged ineffective treatment exposes patients to significant corticosteroid side effects. Always consider IBM in patients over 50 with slowly progressive weakness.

Initial Treatment — Inflammatory Myopathies (PM/DM, not IBM)

💊

Prednisolone

First-line corticosteroid for PM/DM

Adult dose 1 mg/kg/day PO (max 60 mg/day) for 4–6 weeks, then taper over 6–12 months

Route Oral

Duration Maintenance therapy for 1–3 years; many patients require steroid-sparing agents

Renal adjustment None required; monitor glucose, bone density

PBS status ✔ PBS General Benefit

💊

Methotrexate

Steroid-sparing agent — first-line adjunct

Adult dose 7.5–25 mg PO/SC once weekly; titrate over 6–8 weeks

Folic acid 5 mg PO once weekly (not on methotrexate day) — reduces side effects

Renal adjustment Contraindicated if eGFR <30 mL/min/1.73 m²; reduce dose if eGFR 30–60

Monitoring FBC, LFTs, creatinine every 2–4 weeks initially, then every 3 months

PBS status ✔ PBS Authority Required

💊

Azathioprine

Imuran® · Alternative steroid-sparing agent

Adult dose 2–3 mg/kg/day PO; start at 50 mg/day and titrate over 4–6 weeks

Pre-treatment TPMT genotype or enzyme activity — risk of severe myelosuppression in poor metabolisers

Renal adjustment Reduce dose by 25–50% in renal impairment

PBS status ✔ PBS General Benefit

💊

Intravenous Immunoglobulin (IVIg)

For refractory or severe disease

Adult dose 2 g/kg over 2–5 days every 4–6 weeks

Indication Refractory DM/PM, severe dysphagia, rapidly progressive disease, or when other agents are contraindicated

PBS status ⚑ PBS Authority Required

Hereditary Myopathies — Overview

Hereditary myopathies are a genetically heterogeneous group of disorders. Referral to a neuromuscular specialist and clinical genetics service is essential for definitive diagnosis, genetic counselling, and family planning advice.

Condition	Inheritance	Key Clinical Features	Gene / Genetic Test	Key Monitoring
Duchenne Muscular Dystrophy (DMD)	X-linked recessive	Onset 2–5 years; proximal weakness, Gowers' sign, calf pseudohypertrophy, wheelchair by 12 years, respiratory/cardiac failure by 20s	DMD gene (dystrophin); MLPA, sequencing	CK (markedly elevated), cardiac MRI, respiratory function, corticosteroid therapy from age 4–6
Facioscapulohumeral Dystrophy (FSHD)	Autosomal dominant	Facial weakness (inability to whistle/close eyes), scapular winging, foot drop; may be asymmetric; CK normal or mildly elevated	D4Z4 repeat contraction (FSHD1); SMCHD1 variants (FSHD2); molecular testing via Southern blot / optical genome mapping	Audiometry, retinal examination (Coats disease in paediatric onset), respiratory function, cardiac assessment
Myotonic Dystrophy Type 1 (DM1)	Autosomal dominant (CTG expansion)	Distal weakness, grip myotonia, facial weakness (hatchet face), cataracts, cardiac conduction defects, excessive daytime somnolence, insulin resistance	DMPK gene CTG repeat; blood-based PCR / Southern blot	ECG (annual), echocardiogram, HbA1c, sleep studies, ophthalmology review; anaesthetic risk assessment (malignant hyperthermia-like reactions)
Limb-Girdle Muscular Dystrophy (LGMD)	AD or AR (multiple subtypes)	Proximal weakness of shoulder and hip girdles; variable age of onset and severity; CK typically elevated	Multiple genes (sarcoglycans, calpain-3, dysferlin, etc.); next-generation sequencing panel	Cardiac and respiratory monitoring; genetic counselling

ℹ️

Genetic testing in Australia: Comprehensive neuromuscular gene panels are available through Australian clinical genetics services (e.g. Victorian Clinical Genetics Services, SA Pathology Genetics, PathWest, Hunter Genetics). Referral to a clinical geneticist is recommended for all suspected hereditary myopathies to facilitate cascade testing of family members and genetic counselling.

Investigations

Initial Investigations — Primary Care

The following investigations can be ordered in primary care to narrow the differential and guide referral:

Essential

Serum Creatine Kinase (CK)

Markedly elevated (>5× ULN) in active myopathy (DMD, inflammatory myopathy); mildly elevated in some neuropathies and IBM; normal in NMJ disorders and most neuropathies

Essential

Thyroid Function Tests (TSH, fT4)

Hypothyroidism is a common reversible cause of proximal myopathy and elevated CK

Essential

Electrolytes — Potassium, Calcium, Magnesium, Phosphate

Hypokalaemia, hypocalcaemia, and hypomagnesaemia cause acute weakness; hyperkalaemia may mimic periodic paralysis

Essential

HbA1c / Fasting Glucose

Diabetic neuropathy is the most common cause of distal weakness in Australian adults; also relevant if statin myopathy suspected

Essential

Full Blood Count, ESR, CRP

Elevated inflammatory markers in inflammatory myopathy, vasculitis, or infection-related neuropathy

Available

Liver Function Tests

Elevated ALT/AST in myopathy (muscle source) — do not mistake for hepatotoxicity; relevant for statin monitoring

Available

Vitamin D (25-OH)

Deficiency is common in Australia (particularly in ATSI communities and southern states) and contributes to proximal myopathy

Available

Vitamin B12, Folate

Deficiency causes peripheral neuropathy and subacute combined degeneration of the cord

Available

Serum Protein Electrophoresis (SPEP)

Monoclonal gammopathy may be associated with chronic inflammatory demyelinating polyneuropathy (CIDP) or amyloid neuropathy

Available

Autoimmune Screen — ANA, ENA, Myositis-Specific Antibodies

Anti-Jo-1 (antisynthetase syndrome with ILD), anti-Mi-2 (dermatomyositis), anti-SRP (necrotising myopathy), anti-MDA5 (amyopathic DM with ILD), anti-cN1A (IBM). Available through major immunology laboratories

Available

Acetylcholine Receptor (AChR) Antibodies

Positive in ~85% of generalised MG; anti-MuSK antibodies in ~5% of AChR-negative MG; anti-LRP4 in some seronegative patients

Specialist Investigations — Referral-Based

Specialist

Nerve Conduction Studies / Electromyography (NCS/EMG)

Differentiates demyelinating neuropathy (GBS, CIDP) from axonal neuropathy; identifies myopathic vs neurogenic motor unit changes; repetitive nerve stimulation for NMJ disorders. Available at major metropolitan hospitals and some regional centres. MBS Item 11000 series (nerve conduction) / 11600 series (EMG)

Specialist

Muscle Biopsy

Gold standard for inflammatory myopathy diagnosis; distinguishes PM, DM, IBM, necrotising autoimmune myopathy; identifies mitochondrial, metabolic, and structural myopathies. Performed at centres with neuromuscular pathology expertise

Specialist

MRI of Muscle (Thigh or Whole Body)

Identifies patterns of muscle oedema (inflammatory myopathy), fatty infiltration (chronic/heritable), and guides biopsy site selection. Increasingly used as a non-invasive diagnostic tool

Specialist

MRI Spine

Emergency MRI for suspected cord compression; contrast-enhanced for metastatic disease, epidural abscess

Specialist

CT Chest / Abdomen / Pelvis

Malignancy screening in adult dermatomyositis; thymoma assessment in MG

Specialist

Genetic Testing — Neuromuscular Gene Panel

Next-generation sequencing panels for hereditary myopathies, muscular dystrophies, motor neuron disease; clinical genetics referral recommended. Available through VCGS, SA Pathology, PathWest, Hunter Genetics. Medicare-funded under MBS Item 73289 (whole exome) or as state-funded testing

Specialist

Single Fibre EMG

Most sensitive test for NMJ disorders (sensitivity >95% for MG); may be positive when AChR antibodies are negative; available at select tertiary centres

Referral

Edrophonium (Tensilon) Test

Largely replaced by antibody testing and ice-pack test; may be used in specialist settings when other tests are inconclusive; requires cardiac monitoring due to bradycardia risk

ℹ️

MBS item numbers for neuromuscular investigations: Nerve conduction studies (MBS Items 11000–11015), EMG (MBS Items 11600–11615), and muscle biopsy (MBS Item 30002) are claimable under Medicare. Genetic testing may be funded through state-based programs or Medicare for qualifying clinical scenarios. Always confirm current MBS schedules.

Special Populations

🤰

Pregnancy

Myasthenia gravis: Exacerbations may occur during pregnancy and postpartum. Pyridostigmine is safe in pregnancy — continue at current dose. Avoid IVIg in the first trimester unless essential (limited safety data, but generally considered lower risk than alternatives).

Inflammatory myopathy: Dermatomyositis flare may occur postpartum. Methotrexate and azathioprine (except at doses >2 mg/kg) are teratogenic — discontinue and use prednisolone alone or switch to ciclosporin/tacrolimus with specialist guidance.

Myotonic dystrophy: Risk of severe congenital myotonic dystrophy in offspring (especially if maternal CTG expansion >1,000 repeats); genetic counselling mandatory pre-conception. Anaesthetic risk — avoid suxamethonium; use non-depolarising agents cautiously.

GBS: Rare in pregnancy; IVIg is the preferred treatment. Monitor for respiratory compromise with heightened vigilance due to reduced FVC in pregnancy.

Pyridostigmine (Mestinon®): Safe in pregnancy and breastfeeding. ✔ PBS General Benefit

Coordinate care between neurology, obstetrics, and anaesthetics for all neuromuscular conditions in pregnancy.

👶

Paediatrics

Duchenne muscular dystrophy: Suspect in boys with delayed motor milestones, waddling gait, Gowers' sign, calf pseudohypertrophy, and elevated CK (>10,000 U/L). Refer to paediatric neurology urgently. Corticosteroids (deflazacort or prednisolone) are standard of care from age 4–6 years to prolong ambulation.

Juvenile myasthenia gravis: Presents similarly to adults; thymectomy may be considered early in disease course. Paediatric dosing of pyridostigmine: 1 mg/kg/dose every 4–6 hours.

Paediatric dermatomyositis: More common than polymyositis in children; calcinosis is a significant complication. Treatment is with corticosteroids plus methotrexate. Refer to paediatric rheumatology.

GBS in children: Similar presentation to adults; IVIg is first-line treatment. Lower threshold for ICU admission due to rapid deterioration risk.

Pyridostigmine (Mestinon®): Paediatric dose 1 mg/kg/dose PO every 4–6 hours. ✔ PBS General Benefit

Deflazacort (Emflaza®): 0.9 mg/kg/day PO for DMD; fewer metabolic side effects than prednisolone. ⚑ PBS Authority Required

All children with suspected neuromuscular disease should be referred to a paediatric neurologist. Newborn screening for DMD is under investigation in Australia but not yet routine.

👴

Elderly

Inclusion body myositis: Most common acquired myopathy in patients over 50 years. Often misdiagnosed as polymyositis, leading to years of ineffective corticosteroid treatment. Finger flexor and quadriceps weakness is characteristic.

Statin myopathy: A leading cause of proximal myopathy in older adults. CK may be normal or elevated. Trial of statin cessation for 3 months with CK monitoring is recommended if suspected.

Late-onset myasthenia gravis: Increasing incidence in patients over 60; may be mistaken for stroke or age-related decline. AChR antibodies positive in ~90%.

Polypharmacy review: Many medications can cause or exacerbate weakness — corticosteroids, statins, aminoglycosides, fluoroquinolones, colchicine, amiodarone, lithium. Medication review is essential.

Falls risk assessment is critical in elderly patients with neuromuscular weakness. Refer to physiotherapy and occupational therapy for mobility aids and home safety assessment.

🫘

Renal Impairment

Uraemic myopathy/neuropathy: Common in chronic kidney disease (CKD stages 4–5); contributes to proximal weakness and restless legs. Improves with renal transplantation.

Methotrexate: Contraindicated if eGFR <30 mL/min/1.73 m² for inflammatory myopathy treatment; reduce dose for eGFR 30–60.

IVIg: Use with caution in renal impairment — sucrose-containing formulations are nephrotoxic; prefer Intragam® P (glycine-stabilised). Adequate hydration essential.

Azathioprine: Reduce dose by 25–50% in renal impairment; monitor FBC closely.

Colchicine: Used in some myopathies (familial Mediterranean fever-related); reduce dose in CKD (avoid if eGFR <10) due to risk of neuromyopathy. ✔ PBS General Benefit

Check potassium, calcium, magnesium, and phosphate — electrolyte disturbances in CKD may independently cause or worsen weakness.

🫁

Hepatic Impairment

Hepatic myopathy: Liver disease may contribute to muscle wasting (sarcopenia) and steroid myopathy in patients on corticosteroids for autoimmune hepatitis.

Azathioprine: Use with caution in hepatic impairment; monitor LFTs. Hepatotoxicity may be confused with myopathy-related transaminase elevation.

Methotrexate: Avoid in significant hepatic impairment (Child-Pugh B/C); contraindicated with active liver disease or significant alcohol use.

LFTs interpretation: CK (and AST/ALT from muscle) may be elevated in myopathy — do not attribute to liver disease without checking CK.

Distinguish between hepatogenic and myogenic causes of elevated transaminases by checking CK and GGT simultaneously.

🛡️

Immunocompromised

Opportunistic infections: CMV polyradiculopathy, VZV segmental motor weakness, and HIV-associated neuromuscular disease should be considered in immunocompromised patients with acute weakness.

Medication-related: Immunosuppressive agents (corticosteroids, ciclosporin, tacrolimus) may cause myopathy or exacerbate existing neuromuscular conditions.

Critical illness polyneuropathy/myopathy: Common after prolonged ICU admission; presents with flaccid weakness and areflexia after recovery from sepsis or multi-organ failure. Distinguish from GBS by the clinical context and NCS/EMG findings.

Immunoglobulin replacement: Patients on long-term IVIg for MG or CIDP who develop recurrent infections may have secondary IgA deficiency or IgG subclass deficiency.

Immunocompromised patients receiving IVIg should be monitored for transfusion-transmitted infections, although modern manufacturing processes have significantly reduced this risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Diabetes-related neuropathy burden

Aboriginal and Torres Strait Islander Australians experience type 2 diabetes at rates 3–4 times higher than non-Indigenous Australians (AIHW, 2023). Diabetic peripheral neuropathy is the most common cause of distal weakness and foot complications in this population. Annual diabetic foot screening with monofilament testing should be integrated into chronic disease management plans at Aboriginal Community Controlled Health Services (ACCHS).

Geographic and specialist access barriers

Many Aboriginal and Torres Strait Islander Australians live in remote and very remote areas where neurology, rheumatology, and clinical genetics services are unavailable. Telehealth consultations through specialist outreach programmes (e.g. Royal Flying Doctor Service, state-based outreach clinics) are essential for timely diagnosis and management. NCS/EMG and muscle biopsy are available only in metropolitan or major regional centres, requiring patient transport and accommodation support.

Culturally safe communication

Discussions about progressive neuromuscular conditions, genetic diagnoses, and end-of-life care require culturally appropriate communication. Engage Aboriginal Health Workers and Practitioners (AHWPs) as key members of the care team. Use plain language, visual aids, and ensure adequate time for questions. Recognise the role of family and community in decision-making processes.

Vitamin D deficiency

Despite high UV exposure, vitamin D deficiency is prevalent in Aboriginal and Torres Strait Islander communities, particularly in southern Australia and in communities where cultural practices involve covering skin. Vitamin D deficiency contributes to proximal myopathy and should be assessed as part of the workup. Supplementation with cholecalciferol 1,000–4,000 IU daily is PBS-listed as a general benefit.

Delayed presentation and diagnostic delay

Studies from the Australian Neuromuscular Disease Registry and AIHW data indicate that Aboriginal and Torres Strait Islander Australians with neuromuscular conditions may experience longer diagnostic delays due to reduced access to specialist services, implicit bias in clinical assessment, and competing health priorities (cardiovascular disease, renal disease, infections). Proactive screening and supported referral pathways through ACCHS can reduce these disparities.

Medication access and PBS considerations

Aboriginal and Torres Strait Islander Australians with a valid concession card access PBS medications at reduced or no cost under the Closing the Gap PBS Co-Payment Programme. Ensure prescriptions are written with the CTG flag to reduce out-of-pocket costs for immunosuppressants, pyridostigmine, and corticosteroids. Coordinate medication supply with remote area pharmacists and ACCHS pharmacies.

ℹ️

Resources for Aboriginal and Torres Strait Islander neuromuscular health: RHDAustralia (rhdaustralia.org.au), AIHW Aboriginal and Torres Strait Islander Health Performance Framework, Australian Indigenous HealthInfoNet (healthinfonet.ecu.edu.au), and the National Aboriginal Community Controlled Health Organisation (NACCHO). For genetic counselling resources, consult the Australian Indigenous Genomics Alliance.

📚 References

1. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683.
2. Bershad EM, Feen ES, Suarez JI. Myasthenia crisis. Curr Treat Options Neurol. 2011;13(1):67–79.
3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964.
4. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep. 2013;13(1):321.
5. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
6. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023. Available at: aihw.gov.au.
7. Wandrag L, Garg S, Grzechnik E, et al. The Australian Neuromuscular Disease Registry: a national approach to improving outcomes. J Neuromuscul Dis. 2021;8(s2):S323–S331.
8. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.
9. Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24(5):457–462.
10. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122.
11. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93.
12. Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy. Neurology. 2015;85(4):357–364.
13. Gourie-Devi M. Guillain–Barré syndrome in pregnancy: a review. Ann Indian Acad Neurol. 2018;21(2):109–115.
14. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2023. [Relevant to genetic testing consent frameworks].
15. Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. Melbourne: RACGP; 2020. [Chapter on diabetic neuropathy screening].